Holen Sie sich die Stockscreener-App
215.75
1.43%
3.04
Schlusskurs vom Vortag:
$212.71
Offen:
$210
24-Stunden-Volumen:
1.45M
Relative Volume:
1.65
Marktkapitalisierung:
$10.39B
Einnahmen:
$4.03B
Nettoeinkommen (Verlust:
$-182.84M
KGV:
-57.38
EPS:
-3.7603
Netto-Cashflow:
$391.29M
1W Leistung:
+16.62%
1M Leistung:
+37.66%
6M Leistung:
+5.94%
1J Leistung:
+42.32%
1-Tages-Spanne:
$210.00
$217.19
1-Wochen-Bereich:
$178.92
$217.19
52-Wochen-Spanne:
$144.26
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
215.75 | 10.25B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-05-29 | Hochstufung | CLSA | Hold → Outperform |
| 2026-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories lands Morgan Stanley upgrade, shares in analyst focus - Ad-hoc-news.de
Enterprise value to revenue forward of Charles River Laboratories International, Inc. – NYSE:CRL - TradingView
Enterprise value to revenue forward of Charles River Laboratories International, Inc. – DUS:RV6 - TradingView
Enterprise value to EBIT forward of Charles River Laboratories International, Inc. – NYSE:CRL - TradingView
Enterprise value to EBIT forward of Charles River Laboratories International, Inc. – MUN:RV6 - TradingView
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
RV6 Forecast — Price Target — Prediction for 2027 - TradingView
Charles River Laboratories International Inc (CRL)'s Uncertain F - GuruFocus
Is Charles River (CRL) Quietly Redefining Its Moat Through Lilly’s AI-Driven TuneLab Collaboration? - Yahoo Finance
How is Charles River Laboratories’ stock performance compared to other health care stocks? - MSN
Charles River Laboratories analyst calls stay supportive, shares with a clear Wall Street consensus - Ad-hoc-news.de
Enterprise value to revenue forward of Charles River Laboratories International, Inc. – MUN:RV6 - TradingView
Price to sales forward of Charles River Laboratories International, Inc. – MUN:RV6 - TradingView
Charles River Laboratories International Inc (CRL) Stock Up 5.2% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Charles River Laboratories International, Inc. Actuals & Estimates (NYSE:CRL) - TradingView
Charles River Laboratories lands Morgan Stanley upgrade, shares in S&P 500 medtech spotlight - Ad-hoc-news.de
Charles River Labs, Thursday chart focus keeps shares under review - Ad-hoc-news.de
CRL Forecast — Price Target — Prediction for 2027 - TradingView
Charles River (CRL) Deepens Lilly AI Partnership: What Does TuneLab Access Mean for Its Moat? - simplywall.st
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Charles River Laboratories International Jumps 8.1% in Broad Rally - AlphaStreet
Charles River upgraded, IQVIA downgraded as Morgan Stanley revisits CRO coverage - MSN
2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500
Charles River Laboratories consensus in focus, shares under Wall Street scrutiny - Ad-hoc-news.de
Charles River Laboratories International Inc - TradingKey
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - Yahoo Finance
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River Laboratories consensus in focus, shares tracked ahead of next earnings - Ad-hoc-news.de
How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks? - Yahoo Finance
Charles River Laboratories Inte (CRL): Investor Outlook Reveals 16.4% Potential Upside Amidst Robust Buy Ratings - DirectorsTalk Interviews
Charles River Labs StockMorgan Stanley upgrade highlights biopharma tailwind - AD HOC NEWS
Charles River Laboratories International (CRL) Stock Could Be 41% Undervalued After Lilly Tie Up And Upgrade - simplywall.st
Why Charles River Labs’ Luminex immunoassay service matters for biotech teams - AD HOC NEWS
Charles River collaborates with Lilly TuneLab platform - Yahoo Finance
Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise - BioSpace
CRL News | CHARLES RIVER LABORATORIES (NYSE:CRL) - ChartMill
Global Cell and Gene Therapy CDMO Market Anticipating Remarkable Growth at a CAGR of ~24% by 2034 | DelveInsight - GlobeNewswire Inc.
Why Charles River Labs leans on the Microbial Solutions Celsis platform for faster QC - AD HOC NEWS
Charles River Laboratories International Inc (CRL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Charles River Laboratories International Inc (CRL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Charles River Laboratories International Inc (CRL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
What Charles River Laboratories (CRL)'s Morgan Stanley Upgrade Means For Shareholders - simplywall.st
Charles River Laboratories International Inc (CRL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Charles River Laboratories International Inc (CRL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Charles River Laboratories International Inc (CRL) Institutional Confidence - TradingKey
Charles River Laboratories International Inc (CRL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Morgan Stanley Upgrades Charles River Laboratories (CRL) Amid Bi - GuruFocus
Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $220.29, Implies 19% Upside - TradingView
Charles River upgraded, IQVIA downgraded at Morgan Stanley - Seeking Alpha
This Charles River Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):